Rockwell Medical Analyst Ratings
Rockwell Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/04/2023 | 436.59% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 09/28/2023 | 436.59% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 08/15/2023 | 436.59% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 07/17/2023 | 436.59% | HC Wainwright & Co. | $9 → $11 | Maintains | Buy |
| 05/30/2023 | 339.02% | HC Wainwright & Co. | $7 → $9 | Maintains | Buy |
| 05/02/2023 | 241.46% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/04/2023 | 241.46% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/13/2023 | 241.46% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/08/2023 | 241.46% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 08/30/2022 | 290.24% | HC Wainwright & Co. | $3 → $8 | Maintains | Buy |
| 01/18/2022 | 46.34% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 09/07/2021 | 143.9% | HC Wainwright & Co. | $5.5 → $5 | Maintains | Buy |
| 02/08/2021 | 168.29% | HC Wainwright & Co. | $9 → $5.5 | Maintains | Buy |
| 04/07/2020 | 339.02% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 11/12/2019 | 192.68% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 06/25/2019 | 436.59% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
| 06/24/2019 | 387.8% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 10/19/2018 | 436.59% | IFS Securities | → $11 | Downgrades | Strong Buy → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 10/04/2023 | 436.59% | HC Wainwright公司 | →$11 | 重申 | 购买→购买 |
| 09/28/2023 | 436.59% | HC Wainwright公司 | →$11 | 重申 | 购买→购买 |
| 2023年08月15日 | 436.59% | HC Wainwright公司 | →$11 | 重申 | 购买→购买 |
| 07/17/2023 | 436.59% | HC Wainwright公司 | $9→$11 | 维护 | 买 |
| 2023年05月30日 | 339.02% | HC Wainwright公司 | $7→$9 | 维护 | 买 |
| 05/02/2023 | 241.46% | HC Wainwright公司 | →$7 | 重申 | →购买 |
| 04/04/2023 | 241.46% | HC Wainwright公司 | →$7 | 重申 | →购买 |
| 02/13/2023 | 241.46% | HC Wainwright公司 | →$7 | 重申 | →购买 |
| 02/08/2023 | 241.46% | HC Wainwright公司 | $8→$7 | 维护 | 买 |
| 2022年08月30日 | 290.24% | HC Wainwright公司 | $3→$8 | 维护 | 买 |
| 01/18/2022 | 46.34% | HC Wainwright公司 | $5→$3 | 维护 | 买 |
| 09/07/2021 | 143.9% | HC Wainwright公司 | $5.5→$5 | 维护 | 买 |
| 02/08/2021 | 168.29% | HC Wainwright公司 | $9→$5.5 | 维护 | 买 |
| 04/07/2020 | 339.02% | HC Wainwright公司 | $11→$9 | 维护 | 买 |
| 2019年11月12日 | 192.68% | 派珀·桑德勒 | $10→$6 | 维护 | 超重 |
| 2019年06月25日 | 436.59% | 康托·菲茨杰拉德 | →$11 | 开始承保 | →超重 |
| 2019年06月24日 | 387.8% | 派珀·桑德勒 | →$10 | 开始承保 | →超重 |
| 2018年10月19日 | 436.59% | IFS证券 | →$11 | 评级下调 | 强势买入→跑赢大盘 |
What is the target price for Rockwell Medical (RMTI)?
罗克韦尔医疗公司(RMTI)的目标价格是多少？
The latest price target for Rockwell Medical (NASDAQ: RMTI) was reported by HC Wainwright & Co. on October 4, 2023. The analyst firm set a price target for $11.00 expecting RMTI to rise to within 12 months (a possible 436.59% upside). 9 analyst firms have reported ratings in the last year.
罗克韦尔医疗公司(纳斯达克代码：RMTI)的最新目标价是由HC Wainwright&Co.于2023年10月4日报道的。这家分析公司将目标价定为11美元，预计RMTI将在12个月内升至(可能上涨436.59%)。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Rockwell Medical (RMTI)?
罗克韦尔医疗公司(RMTI)最近的分析师评级是多少？
The latest analyst rating for Rockwell Medical (NASDAQ: RMTI) was provided by HC Wainwright & Co., and Rockwell Medical reiterated their buy rating.
罗克韦尔医疗公司(纳斯达克代码：RMTI)的最新分析师评级由HC Wainwright&Co.提供，罗克韦尔医疗公司重申其买入评级。
When is the next analyst rating going to be posted or updated for Rockwell Medical (RMTI)?
罗克韦尔医疗公司(RMTI)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rockwell Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rockwell Medical was filed on October 4, 2023 so you should expect the next rating to be made available sometime around October 4, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与罗克韦尔医疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。罗克韦尔医疗公司的上一次评级是在2023年10月4日提交的，所以你应该预计下一次评级将在2024年10月4日左右的某个时候公布。
Is the Analyst Rating Rockwell Medical (RMTI) correct?
分析师对罗克韦尔医疗公司(RMTI)的评级正确吗？
While ratings are subjective and will change, the latest Rockwell Medical (RMTI) rating was a reiterated with a price target of $0.00 to $11.00. The current price Rockwell Medical (RMTI) is trading at is $2.05, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但罗克韦尔医疗公司(RMTI)的最新评级被重申，目标价在0.00美元至11.00美元之间。罗克韦尔医疗(RMTI)目前的交易价格为2.05美元，在分析师的预测范围内。